The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
Dejan Juric
Consultant or Advisory Role - Novartis
Jean-Charles Soria
No relevant relationships to disclose
Sunil Sharma
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Udai Banerji
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Analia Azaro
No relevant relationships to disclose
Jayesh Desai
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Francois Philippe Ringeisen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Audrey Kaag
Employment or Leadership Position - Novartis
Rajkumar Radhakrishnan
Employment or Leadership Position - Novartis
Florence Hourcade-Potelleret
Employment or Leadership Position - Novartis
Heiko Maacke
Employment or Leadership Position - Novartis
Jordi Rodon Ahnert
No relevant relationships to disclose